Skip to main content

Table 2 Association of promoter methylation with clinic pathologic characteristics of CRC patients (N = 307)

From: DNA methylation of SFRP1, SFRP2, and WIF1 and prognosis of postoperative colorectal cancer patients

Characteristics

Total

SFRP1 N (%)

SFRP2 N (%)

WIF1 N (%)

N

Hypo-M a

Hyper-M b

P value

Hypo-M

Hyper-M

P value

Hypo-M

Hyper-M

P value

All cases

307

55 (17.9)

252 (82.1)

 

264 (86.0)

43 (14.0)

 

224 (73.3)

83 (26.7)

 

Age

   

0.040

  

0.382

  

0.459

  < 45 years-old

33

7 (12.7)

26 (10.3)

 

26 (9.8)

7 (16.3)

 

27 (12.1)

6 (7.2)

 

 45~60 years-old

132

31 (56.4)

101 (40.1)

 

113 (42.8)

19 (44.2)

 

96 (42.9)

36 (43.4)

 

  ≥ 60 years-old

142

17 (30.9)

125 (49.6)

 

125 (47.4)

17 (39.5)

 

101 (45.0)

41 (49.4)

 

Gender

   

0.766

  

0.944

  

0.224

 Male

180

33 (60.0)

147 (58.3)

 

155 (58.7)

25 (58.1)

 

136 (60.7)

44 (53.0)

 

 Female

127

22 (40.0)

105 (41.7)

 

109 (41.4)

18 (41.9)

 

88 (39.3)

39 (47.0)

 

CEA

   

0.930

  

0.207

  

0.824

  < 5 ng/mL

130

23 (41.8)

107 (42.5)

 

108 (40.9)

22 (51.2)

 

94 (42.0)

36 (43.4)

 

  ≥ 5 ng/mL

177

32 (58.2)

145 (57.5)

 

156 (59.1)

21 (48.8)

 

130 (58.0)

47 (56.6)

 

CA19–9

   

0.114

  

0.180

  

0.327

  < 37 U/mL

232

37 (67.3)

195 (77.4)

 

196 (74.2)

36 (83.7)

 

166 (74.1)

66 (79.5)

 

  ≥ 37 U/mL

75

18 (32.7)

57 (22.6)

 

68 (25.8)

7 (16.3)

 

58 (25.9)

17 (20.5)

 

Multiple polyps

   

0.600

  

0.127

  

0.115

 No

220

41 (74.5)

179 (71.0)

 

185 (70.1)

35 (81.4)

 

155 (69.2)

65 (78.3)

 

 Yes

87

14 (25.5)

73 (29.0)

 

79 (29.9)

8 (18.6)

 

69 (30.8)

18 (21.7)

 

Tumor location

   

0.424

  

0.326

  

0.809

 Colon

115

18 (32.7)

97 (38.5)

 

96 (36.4)

19 (44.2)

 

83 (37.1)

32 (38.6)

 

 Rectum

192

37 (67.3)

155 (61.5)

 

168 (63.6)

24 (55.8)

 

141 (62.9)

51 (61.4)

 

TNM Staging

   

0.121

  

0.042

  

0.311

 I- II

163

24 (43.6)

139 (55.2)

 

134 (50.8)

29 (67.4)

 

115 (51.3)

48 (57.8)

 

 III-IV

144

31 (56.4)

113 (44.8)

 

130 (49.2)

14 (32.6)

 

109 (48.7)

35 (42.2)

 

Tumor invasion

   

0.364

  

0.111

  

0.183

 T1- T3

151

24 (42.9)

127 (50.4)

 

125 (47.3)

26 (60.5)

 

105 (46.9)

46 (55.4)

 

 T4

156

31 (56.4)

125 (49.6)

 

139 (52.7)

17 (39.5)

 

119 (53.1)

37 (44.6)

 

Lymph nodes involved

   

0.036

  

0.056

  

0.403

 N0

173

24 (43.6)

149 (59.1)

 

143 (54.2)

30 (69.8)

 

123 (54.9)

50 (60.2)

 

 N1- N2

134

31 (56.4)

103 (40.9)

 

121 (45.8)

13 (30.2)

 

101 (45.1)

33 (39.8)

 

Metastasis status

   

0.231

  

0.165

  

0.384

 M0

284

53 (96.4)

231 (91.7)

 

242 (91.7)

42 (97.7)

 

209 (93.3)

75 (90.4)

 

 M1

23

2 (3.6)

21 (8.3)

 

22 (8.3)

1 (2.3)

 

15 (6.7)

8 (9.6)

 

Pathological classification

   

0.053

  

0.316

  

0.023

 Prominence

199

31 (56.4)

168 (66.7)

 

168 (63.6)

31 (72.1)

 

135 (60.3)

64 (77.1)

 

 Ulceration

86

16 (29.1)

70 (27.8)

 

78 (29.5)

8 (18.6)

 

71 (31.7)

15 (18.1)

 

 Others

22

8 (14.5)

14 (5.5)

 

18 (6.9)

4 (9.3)

 

18 (8.0)

4 (4.8)

 

Histologic classification

   

0.044

  

0.113

  

0.361

 Adenocarcinoma

235

35 (63.6)

200 (79.4)

 

203 (76.9)

32 (74.4)

 

176 (78.6)

59 (71.1)

 

 Mucinous adenocarcinoma

68

19 (34.5)

49 (19.4)

 

59 (22.3)

9 (20.9)

 

45 (20.1)

23 (27.7)

 

 Others

4

1 (1.9)

3 (1.2)

 

2 (0.8)

2 (4.7)

 

3 (1.3)

1 (1.2)

 

Differentiation degree

   

0.011

  

0.083

  

0.255

 Poor

49

15 (27.3)

34 (13.5)

 

46 (17.4)

3 (7.0)

 

39 (17.4)

10 (12.0)

 

 Moderate or well

258

40 (72.7)

218 (86.5)

 

218 (82.6)

40 (93.0)

 

185 (82.6)

73 (88.0)

 
  1. aHypomethylation
  2. bHypermethylation
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us